Stockscreener 앱 받기
135.49
3.03%
3.98
전일 마감가:
$131.51
열려 있는:
$132.89
하루 거래량:
283.21K
Relative Volume:
0.91
시가총액:
$1.60B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.36%
1개월 성능:
+65.21%
6개월 성능:
+150.26%
1년 성능:
+554.54%
1일 변동 폭
$130.53
$138.00
1주일 범위
$127.65
$151.18
52주 변동 폭
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
135.49 | 1.56B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Mizuho | Outperform |
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo
Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada
Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com UK
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat
Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com
Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance
Palvella raises $230M to develop rare skin disease drugs - Stock Titan
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI
Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail
PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis
Palvella prices $200M stock offering at $125 per share - Investing.com Australia
Strategic Update: PVLA Surges Amid New Growth Plans - timothysykes.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up After Analyst Upgrade - MarketBeat
Palvella Therapeutics shares rise to three-year high on upsized offering - Investing.com UK
Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - simplywall.st
What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat
HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector - DirectorsTalk Interviews
Palvella Therapeutics announces pricing of upsized public offering - marketscreener.com
Palvella Therapeutics Announces Pricing of Upsized Public Offering - Bitget
Palvella Therapeutics Announces Pricing Of Upsized Public Offering - TradingView
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance
BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00 - MarketBeat
Palvella launches $150M public stock offering - Investing.com India
Palvella prices $200M stock offering at $125 per share By Investing.com - Investing.com Canada
Palvella Therapeutics Shares Jump as Phase 3 SELVA Trial Hits Primary Endpoint for QTORIN Rapamycin - MarketBeat
Aug Big Picture: Is Innovative Solutions and Support Inc showing insider buyingPortfolio Risk Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Palvella Therapeutics announces proposed public offering - marketscreener.com
Palvella Therapeutics Launches $150 Million Public Offering - marketscreener.com
Palvella Therapeutics Stock Takes a Dive Amidst Market Flux - timothysykes.com
Palvella Therapeutics stock hits 52-week high at 115.95 USD By Investing.com - Investing.com South Africa
Palvella launches $150M public stock offering By Investing.com - Investing.com UK
Palvella Therapeutics Announces Proposed Public Offering - The Manila Times
Strategic Acquisition Expands PVLA’s Market Reach in Europe - StocksToTrade
Truist raises Palvella Therapeutics stock price target on phase 3 data - Investing.com Australia
TD Cowen raises Palvella Therapeutics price target on phase 3 data - Investing.com Canada
Chardan Capital Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $210.00 - MarketBeat
Global Pharma Merger: PVLA’s Game-Changer - timothysykes.com
Stifel raises Palvella Therapeutics price target on trial results By Investing.com - Investing.com Canada
Novo to cut GLP-1 drug prices; Palvella soars on study data - BioPharma Dive
Bladder phase II sinks Protara, LMs phase III wins for Palvella - BioWorld MedTech
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighTime to Buy? - MarketBeat
Palvella stock surges on late-stage trial win (PVLA:NASDAQ) - Seeking Alpha
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):